Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment

NCT03329599 is registered in ClinicalTrials.gov with Northern California Institute of Research and Education as lead sponsor.

NCT NCT03329599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03329599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment
Lead sponsor
Northern California Institute of Research and Education
Phase
Phase 2
Overall status
Completed
Start date
February 14, 2019
Completion date
March 30, 2022
Enrollment
148 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adherence, medication, atherosclerosis, tolerance